释 义 n. 恩杂鲁胺（药名）
例 句 Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression.与接受睾酮抑制治疗的激素敏感的前列腺癌患者相比，恩杂鲁胺显著延长无进展期和总体生存期。
作者： Davis ID
期刊：N Engl J Med
Methods: In this open-label, randomized, phase 3 trial, we assigned patients to receive testosterone suppression plus either open-label enzalutamide or a standard nonsteroidal antiandrogen therapy (standard-care group). The primary end point was overall survival. Secondary end points included progression-free survival as determined by the prostate-specific antigen (PSA) level, clinical progression-free survival, and adverse events.